PL3689365T3 - Zastosowanie peptydów glp-1 o przedłużonym działaniu - Google Patents

Zastosowanie peptydów glp-1 o przedłużonym działaniu

Info

Publication number
PL3689365T3
PL3689365T3 PL20157813.5T PL20157813T PL3689365T3 PL 3689365 T3 PL3689365 T3 PL 3689365T3 PL 20157813 T PL20157813 T PL 20157813T PL 3689365 T3 PL3689365 T3 PL 3689365T3
Authority
PL
Poland
Prior art keywords
peptides
long
acting glp
glp
acting
Prior art date
Application number
PL20157813.5T
Other languages
English (en)
Inventor
Christine Bjørn JENSEN
Mads Frederik RASMUSSEN
Milan Zdravkovic
Peter Kristensen
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of PL3689365T3 publication Critical patent/PL3689365T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
PL20157813.5T 2012-07-01 2013-06-21 Zastosowanie peptydów glp-1 o przedłużonym działaniu PL3689365T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP12174535 2012-07-01
US201261694837P 2012-08-30 2012-08-30
US201261708162P 2012-10-01 2012-10-01
EP12186781 2012-10-01

Publications (1)

Publication Number Publication Date
PL3689365T3 true PL3689365T3 (pl) 2025-11-12

Family

ID=65858459

Family Applications (2)

Application Number Title Priority Date Filing Date
PL20157813.5T PL3689365T3 (pl) 2012-07-01 2013-06-21 Zastosowanie peptydów glp-1 o przedłużonym działaniu
PL13737808.9T PL2866825T3 (pl) 2012-07-01 2013-06-21 <div>ZASTOSOWANIE PEPTYDÓW GLP-1 O PRZEDŁUŻONYM DZIAŁANIU</div>

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL13737808.9T PL2866825T3 (pl) 2012-07-01 2013-06-21 <div>ZASTOSOWANIE PEPTYDÓW GLP-1 O PRZEDŁUŻONYM DZIAŁANIU</div>

Country Status (17)

Country Link
US (2) US9764003B2 (pl)
EP (3) EP2866825B1 (pl)
JP (1) JP6059802B2 (pl)
AU (3) AU2013286177B2 (pl)
BR (1) BR112014032938A2 (pl)
CA (1) CA2877056A1 (pl)
DK (1) DK2866825T3 (pl)
ES (2) ES3041720T3 (pl)
HR (2) HRP20251088T1 (pl)
HU (2) HUE072859T2 (pl)
MX (3) MX376058B (pl)
PL (2) PL3689365T3 (pl)
PT (1) PT2866825T (pl)
RS (2) RS67258B1 (pl)
RU (2) RU2018117557A (pl)
SI (1) SI2866825T1 (pl)
WO (1) WO2014005858A1 (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2651398T3 (pl) 2010-12-16 2018-05-30 Novo Nordisk A/S Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego
DK2696687T3 (en) 2011-04-12 2017-02-06 Novo Nordisk As Double-acylated GLP-1 derivatives
EP4324475A1 (en) 2012-03-22 2024-02-21 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
RS67258B1 (sr) 2012-07-01 2025-10-31 Novo Nordisk As Upotreba dugodelujućih glp-1 peptida
KR20210086717A (ko) 2013-05-02 2021-07-08 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
CN110254223B (zh) * 2014-10-16 2022-03-25 洋马动力科技有限公司 拖拉机
GB201621987D0 (en) * 2016-12-22 2017-02-08 Archer Virgil L See Archer Sheri A Arecor Ltd Novel composition
DE102017106216A1 (de) * 2017-03-22 2018-09-27 Amw Gmbh Extrudierte Depotform zur anhaltenden Wirkstofffreisetzung
HUE066356T2 (hu) 2017-08-24 2024-07-28 Novo Nordisk As GLP-1 készítmények és alkalmazásaik
IL322969A (en) * 2017-10-12 2025-10-01 Novo Nordisk As Semaglutide in medical therapy
GB201720187D0 (en) * 2017-12-04 2018-01-17 Imperial Innovations Ltd Novel Compounds
WO2019149880A1 (en) 2018-02-02 2019-08-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
WO2020028907A1 (en) * 2018-08-03 2020-02-06 Brown University Compositions and methods for improving the bioavailability of glp1 and analogues thereof
WO2020176678A1 (en) * 2019-02-26 2020-09-03 Twist Bioscience Corporation Variant nucleic acid libraries for glp1 receptor
EP3930757A1 (en) 2019-03-01 2022-01-05 President And Fellows Of Harvard College Methods and compositions for protein delivery
HRP20241052T1 (hr) * 2019-11-06 2024-11-08 Novo Nordisk A/S Semaglutid, namijenjen liječenju alzheimerove demencije
AU2020418207A1 (en) * 2019-12-30 2022-08-25 Gan & Lee Pharmaceuticals Co., Ltd. Long-acting GLP-1 compound
TW202140058A (zh) 2020-01-30 2021-11-01 美商美國禮來大藥廠 提派肽（ｔｉｒｚｅｐａｔｉｄｅ）之治療用途
WO2021162532A2 (ko) 2020-02-14 2021-08-19 주식회사 지투지바이오 Glp-1 유사체, 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 미립구를 포함하는 약학적 조성물
PE20221575A1 (es) * 2020-02-18 2022-10-06 Novo Nordisk As Formulaciones farmaceuticas
CN112768087A (zh) * 2020-12-23 2021-05-07 吉林大学 利用孟德尔随机化方法验证索马鲁肽口服制剂预防二型糖尿病的用途
JP2024527528A (ja) * 2021-06-24 2024-07-25 ギラ セラピューティクス インコーポレイテッド 満腹感を誘導する、及び代謝障害を治療するための方法及びキット
US12514908B2 (en) 2021-07-05 2026-01-06 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
FI4408840T3 (fi) 2021-09-27 2025-11-04 Terns Pharmaceuticals Inc Bentsimidatsolikarboksyylihappoja glp-1r-agonisteina
IL312364A (en) 2021-10-25 2024-06-01 Luehr Gary W Compounds as GLP-1R agonists
CA3237751A1 (en) 2021-11-10 2023-05-19 Tyler Brown Ionic liquid compositions
CN115850438B (zh) * 2021-12-28 2023-05-12 北京惠之衡生物科技有限公司 一种长效glp-1衍生物
US12410163B2 (en) 2022-02-23 2025-09-09 Terns Pharmaceuticals, Inc. Compounds as GLP-IR agonists
US20230374096A1 (en) * 2022-05-19 2023-11-23 Vault Bioventures, Inc. Obesity treatment and prevention methods
JP2026502943A (ja) 2022-12-30 2026-01-27 アルギファルマ エーエス 経口投与されるポリペプチド治療剤の全身バイオアベイラビリティを高める組成物および方法
WO2024211898A1 (en) 2023-04-07 2024-10-10 Terns Pharmaceuticals, Inc. Combination comprising a thrbeta agonist anda glp-1r agonist for use in treating a liver disorder or a cardiometabolic disease
CN121843690A (zh) 2023-07-24 2026-04-10 莱兰斯坦福初级大学评议会 用于递送治疗性肽的组合物和方法
KR102930984B1 (ko) * 2024-01-29 2026-02-25 주식회사 티온랩테라퓨틱스 세마글루타이드의 개선된 의료 요법 제공을 위한 비만 및 당뇨 치료용로써, 소수성 이온 페어링 겔레이션을 통한 초기 방출이 제어된 데포 조성물 및 이의 제조방법
WO2025165146A1 (ko) * 2024-01-29 2025-08-07 주식회사 티온랩테라퓨틱스 세마글루타이드 또는 티르제파타이드의 개선된 의료 요법 제공을 위한 비만 및 당뇨 치료용으로써, 소수성 이온 페어링 겔레이션을 통한 초기 방출이 제어된 데포 조성물 및 이의 제조방법
WO2026046328A1 (en) * 2024-08-30 2026-03-05 Beijing Ql Biopharmaceutical Co., Ltd. Dosing regimen of glp-1 conjugates
CN118845644B (zh) * 2024-09-27 2025-01-17 杭州信海医药科技有限公司 一种司美格鲁肽注射液的制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
JP3149958B2 (ja) 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１誘導体
US20030119734A1 (en) 2001-06-28 2003-06-26 Flink James M. Stable formulation of modified GLP-1
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
PT1687019T (pt) 2003-11-20 2018-02-26 Novo Nordisk As Formulações de péptidos que contêm polietileno glicol que são ótimas para produção e para utilização em dispositivos de injeção
EP2494983B1 (en) 2004-11-12 2019-04-24 Novo Nordisk A/S Stable formulations of glp-1
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
WO2007121411A2 (en) 2006-04-14 2007-10-25 Mannkind Corporation Glucagon-like peptide 1(glp-1) pharmaceutical formulations
US20100047762A1 (en) 2007-03-20 2010-02-25 Nippon Kayaku Kabushiki Kaisha Method to monitor drug efficacy in diabetic patients using an assay for 1,5-anhydro-d-glucitol
US20110144010A1 (en) 2007-06-01 2011-06-16 Novo Nordisk A/S Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier
WO2009030774A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
ES2672770T3 (es) 2007-09-05 2018-06-18 Novo Nordisk A/S Derivados del péptido-1 similar al glucagón y su uso farmacéutico
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
DK2373681T3 (en) 2008-12-10 2017-04-24 Glaxosmithkline Llc PHARMACEUTICAL COMPOSITIONS OF ALBIGLUTID
NZ619520A (en) * 2009-02-13 2015-06-26 Boehringer Ingelheim Int Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
CA2784757A1 (en) * 2009-12-16 2011-07-07 Novo Nordisk A/S Double-acylated glp-1 derivatives
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
WO2012016419A1 (zh) 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
PL2651398T3 (pl) * 2010-12-16 2018-05-30 Novo Nordisk A/S Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego
US20130035281A1 (en) * 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102718858B (zh) 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
CN102229668A (zh) 2011-06-03 2011-11-02 浙江贝达药业有限公司 一种glp-1衍生物及其应用
WO2012177929A2 (en) * 2011-06-24 2012-12-27 Amylin Pharmaceuticals, Inc. Methods for treating diabetes with extended release formulations of glp-1 receptor agonists
RS67258B1 (sr) 2012-07-01 2025-10-31 Novo Nordisk As Upotreba dugodelujućih glp-1 peptida

Also Published As

Publication number Publication date
AU2020202573A1 (en) 2020-05-07
WO2014005858A1 (en) 2014-01-09
CA2877056A1 (en) 2014-01-09
EP3689365B1 (en) 2025-08-06
JP6059802B2 (ja) 2017-01-11
AU2018202504B2 (en) 2020-05-07
PT2866825T (pt) 2020-07-15
SI2866825T1 (sl) 2020-07-31
RU2657573C2 (ru) 2018-06-14
EP4406593A2 (en) 2024-07-31
AU2013286177B2 (en) 2018-04-26
DK2866825T3 (da) 2020-06-08
JP2015522573A (ja) 2015-08-06
PL2866825T3 (pl) 2021-02-22
EP2866825B1 (en) 2020-04-08
RS67258B1 (sr) 2025-10-31
EP3689365A1 (en) 2020-08-05
MX2014014946A (es) 2015-04-08
BR112014032938A2 (pt) 2017-08-01
AU2018202504A1 (en) 2018-05-10
AU2020202573B2 (en) 2023-04-20
MX366405B (es) 2019-07-08
MX2020010693A (es) 2020-11-06
ES3041720T3 (en) 2025-11-14
RS60432B1 (sr) 2020-07-31
ES2796839T3 (es) 2020-11-30
HUE072859T2 (hu) 2025-12-28
RU2015101826A (ru) 2016-08-20
MX376058B (es) 2025-03-07
MX2019008148A (es) 2019-09-05
EP3689365C0 (en) 2025-08-06
US9764003B2 (en) 2017-09-19
US20150190474A1 (en) 2015-07-09
US10335462B2 (en) 2019-07-02
AU2013286177A1 (en) 2015-01-15
HUE049152T2 (hu) 2020-09-28
US20180085435A1 (en) 2018-03-29
RU2018117557A3 (pl) 2021-08-20
HRP20200889T1 (hr) 2020-09-04
HRP20251088T1 (hr) 2025-11-07
EP2866825A1 (en) 2015-05-06
RU2018117557A (ru) 2019-03-22
EP4406593A3 (en) 2024-10-23

Similar Documents

Publication Publication Date Title
PT2866825T (pt) Uso de péptidos glp-1 de longa ação
ZA201406250B (en) Compositions of glp-1 peptides and preparation thereof
SG11201400432VA (en) Polypeptide vaccine
EP2857033A4 (en) PEPTIDE WITH SKIN PERMEATION
TWI561242B (en) Long-acting peptide analogs
EP2914293A4 (en) METHOD OF USE OF FVIII POLYPEPTIDE
ZA201406082B (en) Use of ccr3-inhibitors
SG11201502680QA (en) Benzamides
IL238651B (en) Long-acting, single-chain insulin analogs
ZA201503127B (en) Peptides
GB201200555D0 (en) Peptide
GB201204868D0 (en) Peptides
GB201223114D0 (en) Novel peptide
GB201217908D0 (en) Retractable footrest
IL234228B (en) Compositions of glp-1 peptides and preparation thereof
EP2891663A4 (en) PEPTIDE DERIVED FROM PSF1
GB201212463D0 (en) Novel use
PT3824876T (pt) Formulações de longa ação de insulinas
GB201221414D0 (en) Trans-locating peptide
GB201220328D0 (en) Peptides
GB201211740D0 (en) Peptides
TWM433525U (en) Structure of calorifier
GB201207895D0 (en) Peptides
GB201200623D0 (en) Peptide
GB201200624D0 (en) Peptide